Cooperative Agreement W81XWH0720054

This $769,366 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand the ontogeny and retention of CD4+ resident memory T cells in the skin that provide protection against cutaneous leishmaniasis, a neglected vector-borne disease. The key objectives are to: 1) determine if precursor CD4+ resident memory T cells develop before skin entry, 2) identify...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $120,226 Project Grant to Fundacao De Apoio A Pesquisa E A Extensao (Fapex) in Salvador, Brazil. This 5-year grant, effective from August 2024 to July 2029, will fund research to characterize the inflammatory response and lipid profiles in obese patients with cutaneous leishmaniasis, a parasitic skin infection. The goal is to understand how...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,326,630 to support research aimed at improving treatment strategies for talaromycosis, a deadly fungal infection common in Southeast Asia. The research objectives are to: 1) Determine if a single high-dose of liposomal amphotericin B is superior to the standard 14-day course of amphotericin B deoxycholate in...

The National Eye Institute (NEI) awarded a $1,313,945 Project Grant (CFDA 93.867 - Vision Research) to the University of Arizona to develop improved topical treatments for herpes simplex virus (HSV) infections of the eye. The project aims to repurpose and reformulate the off-patent drug adefovir dipivoxil (ADV) to enhance its ocular delivery and reduce dosing frequency for better patient adherence. Key objectives include evaluating ADV solution against approved topical antivirals, developing...

This $687,416 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports the development of a cutaneous gel to deliver a small molecule therapeutic for treating diabetic foot ulcers (DFUs). The award recipient, Lynntech Inc., a small business technology development company, is collaborating with Texas Tech University Health Science Center and the University of Miami Miller...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $587,318 to Oregon Health & Science University (OHSU) to support the optimization and development of the next generation of ELQ compounds for malaria treatment and prophylaxis. The key objectives are to identify superior ELQ-596 analogs that demonstrate enhanced anti-malarial potency, oral bioavailability, and...

This $189,635 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel structure-based therapeutic approaches for treating Balamuthia mandrillaris infections, which cause a fatal condition called granulomatous amoebic encephalitis (GAE). The research team, led by investigators at Northeastern University, will focus on understanding the structure-activity...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The funding will be used to establish an effective formulation, conduct toxicological and stability studies, and ultimately file an Investigational New Drug (IND) application...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $216,759 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona to develop a novel transdermal nanoemulsion-based gel formulation containing the antiretroviral drugs dolutegravir and rilpivirine. The goal is to create a non-invasive, long-acting treatment option for pediatric HIV patients, addressing challenges such as lack of age-appropriate formulations, high...

This $479,560 Project Grant awarded by the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development supports the initiation, enrollment, and completion of a Phase 3 clinical trial to evaluate the safety and efficacy of PTX-022 (topical sirolimus gel 3.9% w/w) for the treatment of microcystic lymphatic malformations, a rare and serious condition with no FDA-approved therapies. The funding will also support the New Drug Application (NDA) submission and FDA approval process...